Pfizer Logs Mid-Stage Berobenatide Success, Plans Up to 10 Phase 3 Trials
PFE•Pfizer’s mid-stage berobenatide trial met primary efficacy and safety endpoints, demonstrating comparable weight loss to weekly GLP-1s with no new safety signals and supporting once-monthly dosing. The company plans up to ten Phase 3 trials evaluating berobenatide for long-term obesity management and related cardiometabolic conditions.
1. Positive Mid-Stage Efficacy and Safety
Pfizer’s berobenatide met both primary and key secondary endpoints in its mid-stage obesity study, showing statistically significant mean weight loss versus placebo over the trial period and maintaining a clean safety profile with adverse events consistent with the GLP-1 class.
2. Monthly Dosing Potential
The study confirmed berobenatide’s formulation supports a once-monthly injection, a first for GLP-1 obesity therapies. This less frequent dosing schedule could boost patient compliance compared with established weekly regimens.
3. Planned Phase 3 Development Strategy
Pfizer is moving forward with up to ten Phase 3 trials slated to start by mid-2026, exploring berobenatide’s efficacy in weight maintenance and comorbid cardiometabolic conditions. These trials aim to underpin global regulatory filings and position berobenatide for a commercial launch in a rapidly expanding obesity market.
